Hyperpolarized Helium-3 ( DrugBank: Helium, Helium-3 )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	4

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02163681 (ClinicalTrials.gov)	January 1, 2011	10/6/2014	MRI as a Means to Measure Lung Function: Non-Invasive Imaging in Neonates and Children		Healthy;Cystic Fibrosis (CF);Asthma;Bronchopulmonary Dysplasia (BPD)	Drug: Hyperpolarized Helium-3 MRI of the chest	University of Virginia	Xemed LLC	Completed	4 Months	65 Years	All	77	N/A	United States
2	NCT01161537 (ClinicalTrials.gov)	October 2010	9/7/2010	Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation	A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 =40% Predicted	Cystic Fibrosis	Drug: VX-770;Drug: Placebo	Vertex Pharmaceuticals Incorporated	Cystic Fibrosis Foundation Therapeutics	Completed	12 Years	N/A	All	13	Phase 2	United States
3	NCT00846573 (ClinicalTrials.gov)	November 2008	16/2/2009	Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders	Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders	COPD;Cystic Fibrosis;Asthma;Healthy	Drug: Hyperpolarized Helium-3	University of Massachusetts, Worcester	NULL	Terminated	5 Years	N/A	All	14	N/A	United States
4	EUCTR2017-000672-28-Outside-EU/EEA (EUCTR)		27/03/2017	Study of the Effect of VX-770 on Hyperpolarized Helium-3 MagneticResonance Imaging in Subjects With Cystic Fibrosis and the G551DMutation	A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effectof VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging inSubjects With Cystic Fibrosis, the G551D Mutation, and FEV1 =40%Predicted	cystic fibrosis MedDRA version: 19.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Kalydeco Product Name: ivacaftor Product Code: VX-770 INN or Proposed INN: IVACAFTOR	Vertex Pharmaceuticals Incorporated	NULL	NA			Female: yes Male: yes	17	Phase 2	United States